CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Brimonidine Tartrate/Timolol Maleate

Brimonidine tartrate and Timolol maleate· ingredient timololBeta blocking agents· BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$2.38
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other timolol products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Timolol Maleate$0.75535−$1.63
timolol maleate$0.79615−$1.59
COSOPT$0.92983−$1.45
COSOPT PF$1.08−$1.30
Timolol maleate$1.60−$0.78270
Timoptic in Ocudose$5.94+$3.56
TIMOLOL MALEATE$13.33+$10.95
Timolol GFS$13.33+$10.95

Medicare Part D coverage · CY2026

On 198 plan formularies · typical tier 3
Prior auth 0% · Step therapy 1% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.